A systematic and rational search for novel therapeutic options by pharmacological means, i.e., treatment with small molecules (e.g., chemical/pharmacological chaperones or allosteric modulators) to restore the activity of dysfunctional variants has proven worthwhile in the paradigm of DAT variants associated with DTDS. This evidence concerns the gene SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome.